Investment Information

With transparent disclosure of information and communication with markets,
we will grow along with shareholders.

News Room

News Room Search
News Room List
NO Title Date Viewers
44 HanAll Biopharma Completes Meeting with FDA for next Phase 3 Trials in Dye Eye Disease 2021-02-08 942
43 HanAll Biopharma Net Income for 2020 Increased by 14% Year-on-year to KRW 21.9 Billion 2021-01-19 922
42 HanAll Biopharma HL036 Clinical Trial Results Selected as Best Poster at AAO 2020 2020-11-19 992
41 HanAll Biopharma Recorded KRW 22.1 Billion, KRW 1 Billion, and KRW 3.7 Billion in Sales, Operating Income, and Net Profit for the Third Quarter 2020-10-29 768
40 Chinese Partner HBM Initiated First Dosing of Phase 2 trials of HL161 in MG and ITP in China 2020-10-05 692
39 HL161 (batoclimab) Demonstrated Positive Top-line Results in Phase 2 Clinical Trial in Myasthenia Gravis 2020-08-26 725
38 HanAll Biopharma recorded KRW 22.6 billion and KRW 1.6 billion in sales and operating income for the second quarter 2020-07-29 538
37 HanAll Biopharma Appoints Seung-won Jeong as CEO of HPI, HanAll’s US Subsidiary 2020-06-04 597
36 HBM, HanAll Biopharma’s Chinese Partner, Begins Clinical Trials for Batoclimab with NMOSD Patients 2020-04-22 545
35 Immunovant, HanAll’s partner, Announces Topline data from Phase 2 for IMVT-1401 in TED 2020-03-31 556
1 2 3 현재 페이지4 5 6 7 8